Sofinnova Investments

We’re excited to share news of our latest #investment📢: Marea Therapeutics, a clinical-stage biotechnology company developing next-generation medicines for cardiometabolic diseases, today announced launching with $190 million in combined Series A and B financings (Series B led by Sofinnova Investments ). General Partner, Maha Katabi, PhD, CFA will join the Board of Directors. We are thrilled to partner with such a distinguished team and look forward to supporting Marea’s mission to develop transformative therapies for patients with cardiometabolic disease. #innovation #cardiometabolic #biotech #funding Read the full press release here: https://lnkd.in/eM5MrHtD

Sofinnova Portfolio News: 🎉 Congratulations to Abraham (Abe) Ceesay, Troy Ignelzi, and the entire team at Rapport Therapeutics on such an incredible milestone!

Sofinnova Investments is excited to be on-site at #BIO2024 this week in San Diego! 🌍🔬 Join us as Jakob Dupont, MD MA, Executive Partner, shares his expertise on two panels: 📆 AI in Oncology: Wednesday, June 5th at 3pm. Discover how artificial intelligence is revolutionizing cancer treatment and research. 📆 Inside the VC Playbook: Thursday, June 6th at 10:15am. Gain valuable insights into venture capital funding and overcoming obstacles in challenging markets for success. We look forward to connecting! #AIinOncology #VCFunding #HealthcareInnovation #BIO2024 

#ICYMI: Our Executive Partner, Jakob Dupont, MD MA was a panelist at #LABEST2024 Main-Event Day on Thursday, May 23rd, at the UCLA Luskin Center. It was an honor to join such a distinguished panel of experts in venture capital for a discussion on "The Latest Trends in Venture Capital Investing." Moderated by Josh Green, Chairman Emeritus of the National Venture Capital Association, the panel also featured insights from: 🌟 Mira Chaurushiya, Managing Director, Westlake Village Biopartners 🌟 Sahil Chopra, Principal, Vertex Ventures HC 🌟 Stacy Feld, Regional Head, West North America, J&J Innovation The discussion centered around the current landscape of venture capital, exploring emerging trends and shared perspectives on future opportunities in the industry. A big thank you to everyone who attended and contributed to the vibrant discussion. Looking forward to seeing how these trends will shape the future of venture capital! #VentureCapital #Investing #LABEST #UCLA #Innovation

🎉A huge thank you to Cesar Perez-Ramirez, PhD, Eric Hsu, Erin Huiting, Heraclitos Lefcochilos-Fogelquist, and Urjeet Khanwalkar for your time and #dedication while working with us at Sofinnova Investments! 💫It’s been an incredible 11 months and we are impressed by everyone’s level of engagement. We look forward to seeing you continue to thrive in your future endeavors! #thankyou  #fellowshipprogram #innovation

Join our team and make an impact in funding tomorrow’s cures. #innovation

We’re excited to co-lead a $100M Series A in Seaport Therapeutics alongside ARCH Venture Partners, Third Rock Ventures, and Seaport founder PureTech Health. 🚀🚀🚀 Seaport is advancing a clinical-stage pipeline of novel #neuropsychiatric medicines powered by its proprietary Glyph™ Technology Platform, which leverages the lymphatic system to create new medicines building on clinically validated mechanisms. “Seaport has the potential to meaningfully change the lives of patients with neuropsychiatric disorders,” said James H., M.D., Ph.D., Managing Partner at Sofinnova Investments. “We’ve had the pleasure of knowing Steven Paul and Daphne Zohar for a number of years, as one of the investors in Karuna, and we believe this team has the unique expertise to help solve the challenges of treating serious mental health conditions. I am eager to support Seaport as an investor and board member as the team continues to advance its clinical-stage pipeline of novel therapeutics.” Read the press release:  https://lnkd.in/gG9qvmv7

🎉 Maha Katabi, PhD, CFA featured in the latest National Venture Capital Association #MemberSpotlight highlighting Sofinnova Investments passion for: ☑ Funding healthcare #innovation ☑ Commitment to scientific #expertise ☑ Focus on patient #impact ☑ Collaboration within the #ventureecosystem 💫 "At Sofinnova, we are funding scientific and medical innovation to develop tomorrow’s cures. Value creation driven by innovation across disease spectrums remains a priority as we seek to improve the lives of patients through science."

🧬 We are excited to partner with the Avenzo Therapeutics team as they continue to develop their #oncology pipeline and expand the company. ✨ Executive Partner, Jakob Dupont, MD MA will join the Board of Directors. “We see significant opportunity with AVZO-021 and this team to advance potential best-in-class therapies for some of the most pressing needs in oncology today,” said Jakob Dupont, M.D. “I have been impressed by the progress Avenzo has made to date and look forward to supporting Athena and the Board as they advance their emerging oncology pipeline and grow their promising company.” #cancer #solidtumors #innovation #biotechfinancing

📢 Congratulations, Capstan Therapeutics, on the closing of an oversubscribed $175M Series B financing!   We are proud to support Capstan and their mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA-based therapies. #RNA #autoimmunedisorders #biotech #funding RA Capital Management, Forbion, Johnson & Johnson Innovation JJDC Inc, Mubadala, Perceptive Advisors Read the full press release here: https://lnkd.in/gHDcZ9Ud